Co-Authors
This is a "connection" page, showing publications co-authored by Robert Flisiak and Jerzy Jaroszewicz.
Connection Strength
4.226
-
Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study. Pol Arch Intern Med. 2021 01 29; 131(1):103-110.
Score: 0.921
-
Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study. J Inflamm Res. 2021; 14:3359-3366.
Score: 0.239
-
Impact of Kidney Failure on the Severity of COVID-19. J Clin Med. 2021 May 10; 10(9).
Score: 0.236
-
Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. Pol Arch Intern Med. 2021 05 25; 131(5):487-496.
Score: 0.236
-
Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. J Clin Med. 2021 Apr 09; 10(8).
Score: 0.235
-
Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. Pol Arch Intern Med. 2020 10 29; 130(10):915-918.
Score: 0.228
-
Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 1 as of June 8, 2020. Pol Arch Intern Med. 2020 06 25; 130(6):557-558.
Score: 0.222
-
Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. Pol Arch Intern Med. 2020 04 30; 130(4):352-357.
Score: 0.219
-
Chronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients. Clin Exp Hepatol. 2019 Mar; 5(1):75-80.
Score: 0.202
-
siRNA drug development against hepatitis B virus infection. Expert Opin Biol Ther. 2018 06; 18(6):609-617.
Score: 0.192
-
Normalizing serum hepcidin but not a-1-antitrypsin level during effective treatment of chronic hepatitis C. Clin Exp Hepatol. 2017 Dec; 3(4):203-208.
Score: 0.186
-
Serum Concentrations of Th17-Associated Interleukins and Autoimmune Phenomena are Associated with the Degree of Liver Damage in Alcoholic Liver Disease. J Gastrointestin Liver Dis. 2017 Sep; 26(3):269-274.
Score: 0.183
-
Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. Mediators Inflamm. 2017; 2017:3480234.
Score: 0.182
-
The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease. Clin Exp Hepatol. 2017 Sep; 3(3):127-134.
Score: 0.180
-
Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection. Clin Exp Hepatol. 2015 Jun; 1(2):35-38.
Score: 0.156
-
Distribution of HBV genotypes in Poland. Clin Exp Hepatol. 2015 May; 1(1):1-4.
Score: 0.155
-
Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clin Infect Dis. 2019 11 13; 69(11):1969-1979.
Score: 0.053
-
Prophylaxis of hepatitis B virus (HBV) infection reactivation - recommendations of the Working Group for prevention of HBV reactivation. Clin Exp Hepatol. 2019 Sep; 5(3):195-202.
Score: 0.053
-
Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study. Clin Exp Hepatol. 2019 Sep; 5(3):215-223.
Score: 0.053
-
Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol. 2018 Sep; 4(3):153-157.
Score: 0.049
-
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? J Interferon Cytokine Res. 2018 02; 38(2):93-100.
Score: 0.047